劉安庭先生

Mr. Andy A. Liu is the Group CEO of Cellomics Holdings, a leading diagnostic company focusing on oncology liquid biopsy and precision medicine. Mr. Andy Liu has over 25+ years of experience as a Healthcare Executive. He has spent many years with TPG Private Equity as an operator leading the portfolio companies in the life sciences industries. Mr. Liu was previously the President of Asia Pacific and China for IQVia. (also known as IMS Health) Mr. Liu managed the Data Analytics, Digital Solutions, and Commercial and Consulting businesses for the entire Asia Pacific. Mr. Liu was responsible for managing the P&L of the entire region inclusive of 17 regions including China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Taiwan, Bangladesh, Sri Lanka and Pakistan. Mr. Liu has held several executive roles previously including the President of Basebit Technologies, CEO of CW Data Technologies (Wuxi Apptec) and CEO of Ilumi Health (Fosun).  Mr. Liu has spent many years with multinational companies such as Merck and UCB Pharma holding several executive management and leadership positions in the USA and Asia.  Mr. Liu's area of focus is in healthcare product launch and commercialization: inclusive of regulatory approval, pricing, customer acquisition, marketing and sales execution. He has successfully managed and launched products across key therapeutic franchises such as hypertension, atherosclerosis, anticonvulsants, arthritis, antihistamine, osteoporosis and diabetes. He also has strong experience in deal transactions, investments, joint ventures and mergers and acquisitions in the life sciences sector. He has also served as the Board of Directors of ASTRI and HKBIO.